Sunday, October 1, 2017

Weekend Reading - Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C – A Review

Weekend Reading
Greetings, hope you're enjoying this lovely Sunday, thanks for stopping by.

Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
We begin with a recent review article about Gilead's Vosevi, titled; “Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C – A Review” published September 22, 2017, in Gastroenterology & Hepatology.

HCV Genotype 3
Over at NEJM Journal Watch, a small study for HCV genotype 3 patients is reviewed by Atif Zaman, MD, MPH, published last week in Hepatology. The study; Glecaprevir/pibrentasvir for HCV genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase III clinical trial, is available for download over at NATAP. 

New Online
Make sure to check out HCV Advocate's October Newsletter, published today!

Shared on Twitter, by @HenryEChang, is one must read article: Chronic hepatitis C virus infection: Everyone should be treated, published in the multimedia journal Clinical Liver Disease. Here are a few other updates over at CLD as well.

Reviews - Controversies in HCV Management
Chronic hepatitis C virus infection: Everyone should be treated
Authors Steven Flamm
First Published: 29 September 2017
Abstract
Full Text (HTML)
PDF (91.3KB)
PDF (91.3KB)
References
Watch a video presentation of this article
Watch the interview with the author

Reviews - Controversies in HCV Management
Authors Philippe J. Zamor, Mark W. Russo
First Published: 29 September 2017

Reviews - From Operation to the First 30 Days
Innovative care models after liver transplant
Authors C. Burcin Taner, Andrew P. Keaveny
First Published: 29 September 2017
Abstract
Full Text (HTML)
PDF (217.7KB)
PDF (217.7KB)
References
Watch a video presentation of this article
Watch the interview with the author

Begin here...

Enjoy the rest of your weekend!
Tina
Posted by at
File Under , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)